This narrative review describes the complex interplay between GLP-1 signalling and intestinal inflammation, highlighting both the potential benefits and limitations of GLP1 RAs in IBD management, with a particular focus on their promising role in selected obese IBD patients. The gene discussed is GCG; the disease is inflammatory bowel disease.